Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Dev Neurosci ; 62: 15-24, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28760642

ABSTRACT

Neonatal hypoxia ischemia (HI) plays a role in the etiology of several neurological pathologies and causes severe sequelae. Acetylcholine is a neurotransmitter in the central nervous system and cholinesterase inhibitors have demonstrated a positive action over HI induced deficits. In order to evaluate the effects of pre and post-hypoxia administrations of galantamine, a cholinesterase inhibitor, in a model of perinatal HI, Wistar rats in the post-natal day 7 (PND7) were subjected to a combination of unilateral occlusion of the right carotid artery with the exposure to a 1h hypoxia. Intraperitoneal injections of galantamine were administered in two different protocols: one pre and other post-hypoxia. The analysis of brain structures volume at PND45 showed that pre-hypoxia galantamine treatment prevented tissue injury to the ipsilesional hippocampus. Also, immunofluorescence showed HI-induced increase in the number of astrocytes that was prevented by pre-hypoxia treatment. Biochemical analysis was performed in the ipsilesional hippocampus at PND8 and revealed that pre-hypoxia galantamine treatment: 1) prevented the neuronal loss induced by HI; 2) reduced the HI-induced hypertrophy of astrocytes; and 3) caused an increase in the activity of the anti-oxidant enzyme catalase. Overall, treatment with galantamine was able to prevent the brain damage, increase the survival of neurons, reduce astrocytic reaction and increase the activity of the anti-oxidant enzyme catalase in rats submitted to neonatal hypoxia ischemia.


Subject(s)
Brain , Catalase/metabolism , Cholinesterase Inhibitors/administration & dosage , Galantamine/administration & dosage , Gliosis/prevention & control , Hypoxia-Ischemia, Brain/drug therapy , Up-Regulation/drug effects , Age Factors , Animals , Animals, Newborn , Brain/drug effects , Brain/metabolism , Brain/physiology , Drug Administration Schedule , Female , Fluoresceins/metabolism , Glial Fibrillary Acidic Protein/metabolism , Hypoxia-Ischemia, Brain/pathology , Male , Rats , Rats, Wistar , Reactive Nitrogen Species/metabolism , S100 Calcium Binding Protein beta Subunit/metabolism , Superoxide Dismutase/metabolism
2.
Neurochem Res ; 42(2): 552-562, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27885575

ABSTRACT

Neonatal hypoxia-ischemia (HI) is an etiologic component of several neurologic pathologies associated to cognitive impairment. The mechanisms involved in HI-induced tissue damage start immediately after HI and extend for days. Acetylcholine is an important neurotransmitter in the central nervous system and exerts a protector effect on tissue damage by modulating inflammation, and cholinesterase inhibitors have shown neuroprotective properties and their action are often attributed to inhibition of the immune response. The administration of Huperzia quadrifariata alkaloid extract (HqAE), with potent and selective cholinesterase inhibitor properties, will reduce the HI induced behavioral deficits and tissue damage. A total of 84 newborn Wistar rat pups at post natal day 7 (PND7) were subjected to right carotid occlusion followed by 1 h of hypoxia (8% of O2) and i.p. injections of saline, vehicle or HqAE (10 mg/kg). Morris Water Maze and inhibitory avoidance tests were used to assess the cognitive function. Flow cytometry was performed at PND11. Histological analysis was performed at PND45. HqAE treatment was able to prevent the HI induced cognitive deficits in both tests and, at PND45, histological analysis showed that HqAE treatment reduced hippocampus tissue damage. Flow cytometry of the injured hippocampus revealed that the treatment was able to reduce cellular death and the number of infiltrating T cells. Altogether, these results show the therapeutic potential of the Huperzia quadrifariata alkaloid extract to prevent cognitive deficits and histological damage caused by neonatal hypoxia-ischemia, probably by reducing cellular death and T cell mobilization.


Subject(s)
Alkaloids/therapeutic use , Cholinesterase Inhibitors/therapeutic use , Huperzia , Hypoxia-Ischemia, Brain/enzymology , Neuroprotective Agents/therapeutic use , Plant Extracts/therapeutic use , Alkaloids/isolation & purification , Alkaloids/pharmacology , Animals , Animals, Newborn , Cholinesterase Inhibitors/isolation & purification , Cholinesterase Inhibitors/pharmacology , Disease Models, Animal , Female , Hypoxia-Ischemia, Brain/prevention & control , Male , Maze Learning/drug effects , Maze Learning/physiology , Neuroprotective Agents/isolation & purification , Neuroprotective Agents/pharmacology , Plant Components, Aerial , Plant Extracts/isolation & purification , Plant Extracts/pharmacology , Rats , Rats, Wistar , Treatment Outcome
3.
Phytomedicine ; 19(14): 1321-4, 2012 Nov 15.
Article in English | MEDLINE | ID: mdl-23022390

ABSTRACT

Huperzine A, a Lycopodium alkaloid produced by Chinese folk herb Huperzia serrata (Lycopodiaceae), has been shown to be a promising agent for the treatment of Alzheimer's disease due to its potent acetylcholinesterase (AChE) activity, as well its efficacy in the treatment of memory of aged patients. Thus, the effects of two Huperzia species of habitats in Brazil (H. quadrifariata and H. reflexa) with described in vitro AChE inhibition activities were studied and their effects on mice brain AChE inhibition were determined after a single intraperitoneal (i.p.) injection. The alkaloid extracts were administered to mice in various doses (10, 1 and 0.5mg/kg) and acetylcholinesterase activity was measured post mortem in two brain areas using the Ellman's colorimetric method. The AChE activity was found to be significantly reduced in both the cortex and hippocampus, although this activity was less potent than that of reference inhibitor huperzine A (0.5mg/kg). Thus, it appears that H. quadrifariata and H. reflexa alkaloid extracts, shown to inhibit acetylcholinesterase in vitro, also have very potent in vivo effects, suggesting that the Huperzia species may still constitute a promising source of compounds with pharmaceutical interest for Alzheimer's disease.


Subject(s)
Acetylcholinesterase/metabolism , Alkaloids/pharmacology , Alzheimer Disease/metabolism , Brain/drug effects , Cholinesterase Inhibitors/pharmacology , Huperzia/chemistry , Plant Extracts/pharmacology , Alkaloids/therapeutic use , Alzheimer Disease/drug therapy , Animals , Brain/metabolism , Cerebral Cortex/drug effects , Cholinesterase Inhibitors/therapeutic use , Hippocampus/drug effects , Injections, Intraperitoneal , Male , Mice , Mice, Inbred Strains , Phytotherapy , Plant Extracts/therapeutic use , Sesquiterpenes/pharmacology , Sesquiterpenes/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...